Maryland is currently home to 2671 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
NCT05998408
Recruiting
Background: Immune bone marrow failure is a condition that occurs when a person s immune system attacks the cells of the bone marrow. This can lead to diseases including different types of anemias and blood cancers. Some of these diseases can be deadly. Better treatments are needed. Objective: To test a drug (ruxolitinib) in people with different types of immune bone marrow failure. Eligibility: Adults aged 18 and older with an immune bone marrow failure. Design: Participants will be scre... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS
Register for Updates
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
NCT05327023
Recruiting
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high. Researchers want to see if giving the transplant recipient an infusion of lymphocytes (a type of white blood cell) from their transplant donor early after the transplant can reduce that risk. Objective: To learn if giving donor lymphocytes early after a transplant will help reduce the risk of relapse for people with certain blood cancers. Eligibil... Read More
Gender:
ALL
Ages:
Between 12 years and 120 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hematologic Neoplasms
Register for Updates
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
NCT04959175
Recruiting
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD). The chemotherapy drug cyclophosphamide helps reduce the risk and severity of GVHD. Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side effects while maintaining its effectiveness. Such an approach is being used in an ongoing clinical study at the NIH with promising result... Read More
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hematologic Neoplasms
Register for Updates
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
NCT03831958
Recruiting
Background: The pituitary gland produces hormones. A tumor in this gland can cause it to produce too much of the hormone cortisol. Too much cortisol in the body causes Cushing disease. This disease causes many problems. Some of these problems might persist after the disease is cured. Objective: To find out the long-term effects of exposure to high levels of cortisol during childhood and adolescence. Eligibility: People ages 10-42years who were diagnosed with Cushing disease before age 21 an... Read More
Gender:
ALL
Ages:
Between 2 years and 90 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cushing Disease
Register for Updates
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
NCT03300830
Recruiting
Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to cause disease. Some variants are known to cause or affect diseases like cancer. Researchers want to study genetic variants in people with cancer who also have an immunologic disease like HIV. Objective:... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer
Register for Updates
Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers
NCT06874205
Recruiting
Background: PDE4D is a protein in the body that plays a role in thinking and depression. This protein may play a major role in disorders such as Alzheimer disease or major depressive disorder. To learn more about these disorders, researchers want to be able to detect levels of PDE4D in the brain. 11C-JMJ-129 is a new radiotracer (a radioactive substance that highlights parts of the body during imaging scans) that was developed to attach only to PDE4D. Objective: To test the new radiotracer 11... Read More
Gender:
ALL
Ages:
Between 18 years and 101 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy
Register for Updates
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
NCT06730126
Recruiting
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and lymph nodes. Current treatments for ALPS can have many adverse effects. Better treatments for ALPS are needed. Objective: To test a study drug (soquelitinib) in people with ALPS. Eligibility: People aged 16 years and older with ALPS. Design:... Read More
Gender:
ALL
Ages:
Between 16 years and 120 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Autoimmune Lymphoproliferative Syndrome
Register for Updates
The Impact of Heavy Alcohol Use on Saliva and Oral Health
NCT06684483
Recruiting
Background: People with alcohol use disorder (AUD) have a higher rate of dental and gum disease. Poor oral health can increase the risk of other diseases, such as diabetes and stroke. Researchers want to learn more about how to identify developing inflammation in the mouth. They also want to know how improved oral health education and behaviors can affect inflammation in people with AUD. Objective: This study has 2 goals: (1) to test the usefulness of a new questionnaire about oral health and... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Use Disorder, Alcohol Dependence
Register for Updates
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Annapolis, Maryland
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia
NCT05828108
Recruiting
Background: Diamond-Blackfan anemia (DBA) is an inherited disease that affects the bone marrow. People with DBA have chronic anemia that can be severe. Many must have frequent transfusions of red blood cells. Current treatments for DBA all have risks of serious side effects. Better treatments are needed. Objective: To test a new drug (bitopertin) in people with DBA. Eligibility: People aged 18 or older with DBA. Design: Participants will be screened. They will have a physical exam; they w... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Steroid-refractory Diamond-Blackfan Anemia (DBA)
Register for Updates
The Beneficial Effects of Naps on Motor Learning
NCT04312126
Recruiting
Background: Memory consolidation is the process by which memories become stable, long-term representations in the brain. Consolidation of a motor skill is dependent upon sleep. Some research shows that daytime naps improve people s motor performance and memory retention. Researchers want to find out how daytime naps may contribute to learning and support consolidation of motor skill memories. Objective: To learn the role of memory replay during wakeful rest and sleep (naps) in retaining a new... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Stroke
Register for Updates
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
NCT03206060
Recruiting
Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumors can be removed with surgery, and there are no good treatments if the disease has spread. Researchers think a new drug may be able to help. Objective: To learn the safety and tolerability of Lu-177-DOTATATE. Also, to see if it improves the length of time it takes for the cancer to return. Eligibility: Adults who have an inoperable tum... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Register for Updates